GLP Watchdog

Noom vs Push Health

Neither Noom nor Push Health has an FDA warning letter on record. Push Health publishes no GLP-1 price we could capture. Noom starts at $179 a month for compounded semaglutide injection.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Noom / Push Health

Noom logo

Noom

5.8/10

Push Health logo

Push Health

4.1/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$179/moCompounded semaglutide injection
No GLP-1 price published
States
No state list published
No state list published
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026
Visit Noom
Visit Push Health

Neither Noom nor Push Health pays us. Links to them earn nothing. Scores: Noom 5.8, Push Health 4.1. How we are paid

What the record shows

  1. 01

    Neither Noom nor Push Health has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    Push Health publishes no GLP-1 price we could capture. Noom starts at $179 a month for compounded semaglutide injection.

  4. 04

    Only Noom lists a price for compounded semaglutide injection and brand-name tirzepatide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Noom

Push Health

Compounded semaglutide injection

$179/mo

$2,148 a year

Not sold or not priced
Brand-name tirzepatide pen

$349/mo

$4,188 a year

Not sold or not priced
Price includes
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
Not stated
None
Refunds
Refunds only before a prescription is written; renewal charges are not refunded
Full refund if you cancel before the provider writes a prescription; none after

Read off each seller’s own pages. Noom: October 30, 2026. Push Health: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Noom

5.8/10
  • Sells compounded semaglutide injection and brand-name tirzepatide pen, which Push Health does not price
  • Names no compounding pharmacy
Visit Noom

The case for Push Health

4.1/10

The record gives Push Health no edge on this pair.

  • Names no compounding pharmacy
  • Publishes no GLP-1 price
Visit Push Health

Scores

Noom 5.8 · Push Health 4.1 out of 10. Six weighted parts.

Value25%

0.9A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
5.0

User Experience15%

8.0A
vs
B
3.0

Trust & Safety15%

6.5A
vs
B
4.0

Accessibility10%

5.0A
vs
B
5.0

Support10%

4.0A
vs
B
5.0

The score is the same formula for every seller. Payment does not enter it. Method

Noom vs Push Health: questions

Neither Noom nor Push Health has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Noom states you can cancel at any time; refunds: refunds only before a prescription is written; renewal charges are not refunded. Push Health states you can cancel at any time; refunds: full refund if you cancel before the provider writes a prescription; none after.
Neither Noom nor Push Health pays us. Links to them earn nothing. Scores: Noom 5.8, Push Health 4.1.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks